Program
sevabertinib
Also written as “BAY2927088”, “Sevabertinib” and “Sevabertinib (BAY 2927088)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Hepatic Insufficiency, led by Bayer.
Furthest: phase 3, since Jun 5, 20248 company-led studies, 2 open or runningNext primary completion: Oct 28, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 82 open or running | phase 3since Jun 5, 2024 | Jan 15, 2024 | Oct 28, 2027phase 3 · NCT06452277 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2024First study: phase 1 study in Advanced Non-small Cell Lung CancerFirst studyNCT06221475 · 8 enrolled · Netherlands
- Mar 19, 20242 phase 1 studies in Advanced Non-small Cell Lung CancerNCT06378658, NCT06329895
- Apr 7, 2024Phase 1 study in Advanced Non-small Cell Lung CancerNCT06360211 · 15 enrolled · United States
- Jun 5, 2024Phase 3 study in Advanced Non-small Cell Lung Cancer, HER2 MutationNCT06452277 · 444 planned · United States, Argentina, Australia and more
- Dec 18, 2024Phase 2 study in Colorectal NeoplasmsNCT06760819 · 111 planned · United States, Australia, Canada and more
- Jul 18, 2025Phase 1 study in Hepatic InsufficiencyNCT07102095 · 18 enrolled · United States
- Aug 4, 2026Phase 1 study in Healthy ParticipantsNCT07753252 · 42 enrolled · United States
Ahead
- Oct 28, 2027Primary completion: phase 3 study in Advanced Non-small Cell Lung Cancer, HER2 MutationNCT06452277
- Feb 2, 2029Primary completion: phase 2 study in Colorectal NeoplasmsNCT06760819
TargetBeta
“An orally bioavailable, mutant-selective, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| enozertinibrule | oric-pharmaceuticals | phase 2 | 3 |
| EGFR/HER2 Mutant-selective Inhibitor BH-30643rule | blossomhill-therapeutics | phase 2 | 1 |
| GENSCI139rule | Changchun GeneScience Pharmaceutical | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07753252Healthy Participants · United States | 1 | Completed | Oct 8, 2026 | 42 |
| NCT07102095Hepatic Insufficiency · United States | 1 | Completed | Dec 3, 2025 | 18 |
| NCT06760819Colorectal Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Feb 2, 2029 | 111 |
| NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation · United States, Argentina, Australia and more | 3 | Recruiting | Oct 28, 2027 | 444 |
| NCT06360211Advanced Non-small Cell Lung Cancer · United States | 1 | Completed | Jun 28, 2024 | 15 |
| NCT06378658Advanced Non-small Cell Lung Cancer · United States | 1 | Completed | Jun 11, 2024 | 21 |
| NCT06329895Advanced Non-small Cell Lung Cancer · United Kingdom | 1 | Completed | Jun 10, 2024 | 15 |
| NCT06221475Advanced Non-small Cell Lung Cancer · Netherlands | 1 | Completed | Apr 5, 2024 | 8 |
How it is read
Names in the registry
- “BAY2927088”, 4 entries
- “Sevabertinib”, 2 entries
- “Sevabertinib (BAY 2927088)”, 1 entry
- “BAY2927088 coated tablet 10 mg”, 1 entry
- “[14C]-BAY2927088 solution for infusion”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Colorectal Neoplasms, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.